A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

NCT04102189 on ClinicalTrials.gov · last registry update 2025-12-11

A small phase 3 — 201 participants, against a typical 424. The sponsor logged completion for 25 March 2022. Primary outcome, as filed: Change in Body Mass Index (BMI) (Percentage [%]). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 201
Started: 2019-10-07
Primary completion: 2022-03-25 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Body Mass Index (BMI) (Percentage [%])

Conditions studied

Overweight · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.